The FIRST AND ONLY oral dual PI3K-δ and PI3K-γ inhibitor that predominantly targets malignant B cells and the tumor microenvironment1,2

COPIKTRA (duvelisib) is a kinase inhibitor indicated for the treatment of adult patients with1:

  • Relapsed or refractory CLL or SLL after at least 2 prior therapies
  • Relapsed or refractory FL after at least 2 prior systemic therapies. Accelerated approval was based on overall response rate and continued approval may be contingent upon confirmatory trials.

Please see full Prescribing Information including Boxed Warning.

  • CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; PI3K, phosphoinositide 3-kinase; SLL, small lymphocytic lymphoma; δ, delta; γ, gamma.